Yale University
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Yale University sits in the top decile of US sponsors by registered trial count (#13 of 15,742 sponsors by registered trial count).
Yale University: 1,492 sponsored US clinical trials, 254 recruiting.
Yale University sponsors 1,492 registered US clinical trials on ClinicalTrials.gov, 254 of them currently recruiting, and 1,005 completed. 99 of these trials are in Phase 3-4 (later-stage) and 579 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Opioid Use Disorder, with 19 trials.
Top-decile sponsor footprint
Yale University ranks in the top decile of sponsors by registered trial count (#13 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,005 of 1,138 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,492 total, page 18 of 30
Treatment for Nicotine Addiction in Women
NCT02448654
Ketamine Infusion for Adolescent Depression and Anxiety
NCT02579928
Melatonin Treatment for Night-Eating Syndrome
NCT02500017
Enhancement of Therapeutic Learning in OCD Using tDCS
NCT03572543
Modification and Evaluation of the Educational Mobile Games Heroes of Knowledge in Children
NCT02546245
Effects of Brief Training on Craving Regulation
NCT02153749
Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients
NCT02566265
A Smoking Cessation Intervention for Yale Dining Employees
NCT02562521
Nicotinic Cholinergic Modulation as a Novel Treatment Strategy for Aggression Associated With Autism
NCT02552147
Diagnosing and Targeting Mechanisms of Diuretic Resistance in Heart Failure
NCT02546583
Oxytocin and Affect Processing in Posttraumatic Stress Disorder
NCT02546570
Improving Reproductive Fitness Through Pretreatment With Lifestyle Modification in Obese Women With Unexplained Infertility
NCT02432209
Minocycline's Effects on Alcohol Responses in Humans
NCT02187211
Neurofeedback for Obsessive-Compulsive Disorder (OCD)
NCT02206945
Randomized Controlled Trial of Social Network Targeting in Honduras
NCT02694679
Gaze Modification Strategies for Toddlers With Autism Spectrum Disorder
NCT02488226
Full-Endoscopic vs Open Discectomy for the Treatment of Symptomatic Lumbar Herniated Disc
NCT02441959
The Sustained Effects of Ketamine
NCT02708849
A Multi-center, Prospective Evaluation of Infants and Children With Congenital Ichthyosis
NCT02655861
Exercise in Genetic Cardiovascular Conditions
NCT02549664
Does Sweet Taste Potentiate Nicotine Cue Reactivity?
NCT02499757
Pilot Study for Verifying Endotracheal Tube Repositioning Using Ultrasound
NCT02407158
MOMS Hubs- CT Dept of Social Services Block Grant
NCT02459925
Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC
NCT02407171
The Effect of Cognitive Enhancement as a Precursor to Computer Based Training for Cognitive Behavioral Therapy (CBT4CBT)
NCT02174614
Stage III Community-based Efficacy Trial for Mothering From the Inside Out
NCT02955199
Active Surveillance in Prostate Cancer, Imaging to Detect Radiographic Progression as an Endpoint (ASPIRE)
NCT02425592
Intergenerational Blood Pressure Study
NCT03013179
A Psychosocial Program Impact Evaluation in Jordan
NCT03012451
The Effects of Minocycline in Opioid-maintained Patients
NCT02359006
PLUS PINK: HHRP+ Adaptation for Women With HIV Under Community Supervision
NCT03175094
Buprenorphine Treatment for Opioid Dependence
NCT02187198
Role of Glucagon In Glucose Control in Cystic Fibrosis Related Diabetes
NCT02398383
Corticosteroid Dosage for Crohn's Disease Flare
NCT02392286
Window Trial 5-aza in HNSCC, T-tare
NCT02178072
Testing the Interactive Effects of Delta-9-Tetrahydrocannabinol and Pregnenolone
NCT02576912
Investigating the Role of the Polyol Pathway in the Central Nervous System
NCT02272556
Cognitive Behavioral Therapy in Prolonging the Antidepressant Effects of Intravenous Ketamine
NCT02289248
Ketamine Infusion for Social Anxiety Disorder
NCT02083926
The Effect of Artificial Sweeteners (AFS) on Sweetness Sensitivity, Preference and Brain Response in Adults
NCT02335021
PRIME vs Usual Care for Clinical High Risk
NCT02960451
Comparison of Nasal Steroids After FESS in CRSwNP
NCT02194062
Text Messaging for Smoking Cessation in College Health Clinics
NCT02191033
Preventing Hypoglycemia During Exercise With Proactive Snacking on Closed Loop
NCT02135068
Randomized Controlled Trial of Aspirin vs Placebo in the Treatment of Pre-psychosis
NCT02047539
Methionine and PBR28-PET (Peripheral Benzodiazepine Receptors) in Brain Metastases Following Radiosurgery
NCT02433171
A Pilot Analysis of the Association Between Anesthesia Induction Dosing and AKI in the Elderly Population
NCT03699696
Study of Postoperative Chest Tube Management
NCT02282462
A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease
NCT02167256
Treatment of Binge Eating Disorder in Obesity: Naltrexone/ Bupropion Combination Versus Placebo
NCT02317744
What is open in the Yale University pipeline
254 recruiting of 1,492 indexed (17% open); 1,005 completed (67%).
Phase mix: 99 late (III/IV) vs 579 early (I/II) (early-phase heavy).
Top condition: Opioid Use Disorder (19 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Yale University: open-pipeline peers nationwide
Peers matched on 1,492 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
Yale University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,492 trials (± recruiting share)
- Washington University School of Medicine · 1,502 trials · 14% recruiting
- Johns Hopkins University · 1,448 trials · 17% recruiting
- University of Pennsylvania · 1,423 trials · 14% recruiting
- Novartis Pharmaceuticals · 1,375 trials · 8% recruiting
Sponsors near 17% open enrollment (± trial volume)
- NYU Langone Health · 17% recruiting · 1,164 trials
- CSL Behring · 17% recruiting · 71 trials
- Penn State University · 17% recruiting · 219 trials
- University of Hawaii · 17% recruiting · 77 trials
Related
What to do with this Yale University page
1,492 registered trials is a research-attention snapshot, not an endorsement of Yale University or any single study.
- 254 of Yale University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Opioid Use Disorder is the condition Yale University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Opioid Use Disorder trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Yale University pipeline card: 1,492 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.